知搜-全球专利检索

  1. Login
  2. Sign Up
Invention Grant
US07642238B2 Molecular determinants of myeloma bone disease and uses thereof 失效
骨髓瘤骨病的分子决定因素及其用途

  • Patent Title: Molecular determinants of myeloma bone disease and uses thereof
  • Patent Title (中): 骨髓瘤骨病的分子决定因素及其用途
  • Application No.: US11176739
    Application Date: 2005-07-07
  • Publication No.: US07642238B2
    Publication Date: 2010-01-05
  • Inventor: John D. Shaughnessy
  • Applicant: John D. Shaughnessy
  • Agent Benjamin Aaron Adler
  • Main IPC: A61K39/395
  • IPC: A61K39/395
Molecular determinants of myeloma bone disease and uses thereof
Abstract:
To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P
Abstract(Chinese):

为了鉴定多发性骨髓瘤中溶骨性疾病的分子决定因素，将新发诊断多发性骨髓瘤患者的CD138富集血浆细胞中〜12,000个基因的表达谱与没有溶解性病变的放射学证据（n = 28）进行比较， 3例溶解性病变（n = 47）。 两个分泌的WNT信号传导拮抗剂，可溶性卷曲相关蛋白3（SFRP-3 / FRZB）和Dickkopf-1（DKK1）的人类同源物在47例中具有溶骨病变，但在28例缺乏骨病变中仅有16例 P <0.05）。 DKK1和FRZB在来自45个正常骨髓供体的血浆细胞中不表达，或10个Waldenstrom的巨球蛋白血症，一种缺乏骨病的相关浆细胞恶性肿瘤。 这些数据表明这些因素是多发性骨髓瘤骨病的重要介质，这些蛋白质的抑制剂可用于阻断骨骼疾病。

Public/Granted literature
Information query
Espacenet
Patent Agency Ranking
0/0